Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients

NCT01499368 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT01499368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01499368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
495 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis